Becton Dickinson and Co
BDX193.960USD
+0.100+0.05%
Handelsschluss 12/05, 16:00（ET）Kurse um 15 Minuten verzögert
55.36BMarktkapitalisierung
32.99KGV TTM
mehr Informationen über Becton Dickinson and Co Unternehmen
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
Becton Dickinson and Co Informationen
BörsenkürzelBDX
Name des UnternehmensBecton Dickinson and Co
IPO-datumSep 25, 1963
CEOMr. Thomas E. Polen
Anzahl der mitarbeiter74000
WertpapierartOrdinary Share
GeschäftsjahresendeSep 25
AddresseOne Becton Drive
StadtFRANKLIN LAKES
BörseNYSE Consolidated
LandUnited States of America
Postleitzahl07417-1880
Telefon12018476800
Websitehttps://www.bd.com/
BörsenkürzelBDX
IPO-datumSep 25, 1963
CEOMr. Thomas E. Polen
Führungskräfte von Becton Dickinson and Co
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Richard (Rick) Byrd
Mr. Richard (Rick) Byrd
Executive Vice President, President - Interventional Segment
Executive Vice President, President - Interventional Segment
761.54K
+0.94%
Mr. Timothy M. (Tim) Ring
Mr. Timothy M. (Tim) Ring
Independent Director
Independent Director
59.87K
+1.58%
Ms. Shana Carol Neal
Ms. Shana Carol Neal
Chief People Officer, Executive Vice President
Chief People Officer, Executive Vice President
54.82K
+16.58%
Mr. Roland Goette
Mr. Roland Goette
Executive Vice President, President - EMEA
Executive Vice President, President - EMEA
17.21K
+21.15%
Mr. Michael Feld
Mr. Michael Feld
Executive Vice President, President - Life Sciences
Executive Vice President, President - Life Sciences
16.58K
-0.45%
Ms. Catherine M. (Cathy) Burzik
Ms. Catherine M. (Cathy) Burzik
Independent Director
Independent Director
14.81K
+6.70%
Mr. Antoine C. Ezell
Mr. Antoine C. Ezell
Executive Vice President, President, North America, Chief Marketing Officer
Executive Vice President, President, North America, Chief Marketing Officer
11.97K
+28.43%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Director
Independent Director
9.14K
+11.33%
Ms. Michelle Quinn
Ms. Michelle Quinn
Executive Vice President, General Counsel
Executive Vice President, General Counsel
6.93K
+39.80%
Mr. Gregory J. Hayes
Mr. Gregory J. Hayes
Independent Director
Independent Director
6.05K
+659.55%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Richard (Rick) Byrd
Mr. Richard (Rick) Byrd
Executive Vice President, President - Interventional Segment
Executive Vice President, President - Interventional Segment
761.54K
+0.94%
Mr. Timothy M. (Tim) Ring
Mr. Timothy M. (Tim) Ring
Independent Director
Independent Director
59.87K
+1.58%
Ms. Shana Carol Neal
Ms. Shana Carol Neal
Chief People Officer, Executive Vice President
Chief People Officer, Executive Vice President
54.82K
+16.58%
Mr. Roland Goette
Mr. Roland Goette
Executive Vice President, President - EMEA
Executive Vice President, President - EMEA
17.21K
+21.15%
Mr. Michael Feld
Mr. Michael Feld
Executive Vice President, President - Life Sciences
Executive Vice President, President - Life Sciences
16.58K
-0.45%
Ms. Catherine M. (Cathy) Burzik
Ms. Catherine M. (Cathy) Burzik
Independent Director
Independent Director
14.81K
+6.70%
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Medication Delivery Solutions
1.13B
20.55%
Medication Management Solutions
888.00M
16.12%
Pharmaceutical Systems
629.00M
11.42%
Peripheral Intervention
512.00M
9.29%
Specimen Management
470.00M
8.53%
Andere
1.88B
34.09%
Nach RegionUSD
Name
Umsatz
Anteil
United States
3.18B
57.72%
International
2.33B
42.26%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Medication Delivery Solutions
1.13B
20.55%
Medication Management Solutions
888.00M
16.12%
Pharmaceutical Systems
629.00M
11.42%
Peripheral Intervention
512.00M
9.29%
Specimen Management
470.00M
8.53%
Andere
1.88B
34.09%
Aktionärsstatistik
Aktualisiert: Sat, Nov 15
Aktualisiert: Sat, Nov 15
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
11.32%
T. Rowe Price Investment Management, Inc.
5.69%
BlackRock Institutional Trust Company, N.A.
5.17%
State Street Investment Management (US)
4.86%
First Eagle Investment Management, L.L.C.
3.50%
Andere
69.45%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
11.32%
T. Rowe Price Investment Management, Inc.
5.69%
BlackRock Institutional Trust Company, N.A.
5.17%
State Street Investment Management (US)
4.86%
First Eagle Investment Management, L.L.C.
3.50%
Andere
69.45%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
48.62%
Investment Advisor/Hedge Fund
35.74%
Research Firm
2.91%
Pension Fund
2.39%
Bank and Trust
1.46%
Hedge Fund
1.42%
Sovereign Wealth Fund
1.36%
Individual Investor
0.60%
Insurance Company
0.32%
Andere
5.17%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
2848
265.27M
92.55%
-11.28M
2025Q2
2864
264.72M
92.36%
-14.86M
2025Q1
2897
269.10M
93.89%
-12.90M
2024Q4
2874
271.53M
94.56%
-4.62M
2024Q3
2787
266.29M
92.14%
-3.20M
2024Q2
2782
261.01M
90.31%
-2.68M
2024Q1
2797
255.99M
88.58%
-10.13M
2023Q4
2783
259.38M
89.78%
-7.79M
2023Q3
2768
264.64M
91.23%
-591.87K
2023Q2
2787
263.29M
90.78%
-570.64K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
32.17M
11.22%
+4.30M
+15.41%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
16.18M
5.64%
+3.60M
+28.65%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
15.15M
5.29%
+360.45K
+2.44%
Jun 30, 2025
State Street Investment Management (US)
13.41M
4.68%
-579.46K
-4.14%
Jun 30, 2025
First Eagle Investment Management, L.L.C.
8.79M
3.07%
+3.27M
+59.18%
Jun 30, 2025
MFS Investment Management
7.69M
2.68%
+1.58M
+25.78%
Jun 30, 2025
Geode Capital Management, L.L.C.
6.72M
2.35%
+244.20K
+3.77%
Jun 30, 2025
ClearBridge Investments, LLC
3.80M
1.33%
+321.67K
+9.24%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares U.S. Medical Devices ETF
4.25%
FPA Global Equity ETF
3.12%
Cullen Enhanced Equity Income ETF
3.1%
American Century Focused Large Cap Value ETF
3.04%
iShares Large Cap Value Active ETF
2.72%
First Eagle Global Equity ETF
2.66%
Franklin ClearBridge Enhanced Income ETF
2.66%
T Rowe Price Capital Appreciation Equity ETF
2.65%
Brandes US Value ETF
2.26%
First Trust Indxx Medical Devices ETF
1.92%
Mehr Anzeigen
iShares U.S. Medical Devices ETF
Anteil4.25%
FPA Global Equity ETF
Anteil3.12%
Cullen Enhanced Equity Income ETF
Anteil3.1%
American Century Focused Large Cap Value ETF
Anteil3.04%
iShares Large Cap Value Active ETF
Anteil2.72%
First Eagle Global Equity ETF
Anteil2.66%
Franklin ClearBridge Enhanced Income ETF
Anteil2.66%
T Rowe Price Capital Appreciation Equity ETF
Anteil2.65%
Brandes US Value ETF
Anteil2.26%
First Trust Indxx Medical Devices ETF
Anteil1.92%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
5.54B
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Jan 28, 2025
BDX.NB Interim Cash Dividend of gross USD 1.04 paid on Mar 31, 2025 going ex on Mar 10, 2025
Mar 10, 2025
Mar 31, 2025
Mar 10, 2025
Nov 07, 2024
BDX.NB Final Cash Dividend of gross USD 1.04 paid on Dec 31, 2024 going ex on Dec 09, 2024
Dec 09, 2024
Dec 31, 2024
Dec 09, 2024
Jul 23, 2024
BDX.NB Interim Cash Dividend of gross USD 0.95 paid on Sep 30, 2024 going ex on Sep 09, 2024
Sep 09, 2024
Sep 30, 2024
Sep 09, 2024
Apr 30, 2024
BDX.NB Interim Cash Dividend of gross USD 0.95 paid on Jun 28, 2024 going ex on Jun 10, 2024
Jun 10, 2024
Jun 28, 2024
Jun 10, 2024
Jan 23, 2024
BDX.NB Interim Cash Dividend of gross USD 0.95 paid on Mar 29, 2024 going ex on Mar 07, 2024
Mar 08, 2024
Mar 29, 2024
Mar 07, 2024
Nov 09, 2023
BDX.NB Final Cash Dividend of gross USD 0.95 paid on Dec 29, 2023 going ex on Dec 07, 2023
Dec 08, 2023
Dec 29, 2023
Dec 07, 2023
Jul 25, 2023
BDX.NB Interim Cash Dividend of gross USD 0.91 paid on Sep 29, 2023 going ex on Sep 07, 2023
Sep 08, 2023
Sep 29, 2023
Sep 07, 2023
Apr 25, 2023
BDX.NB Interim Cash Dividend of gross USD 0.91 paid on Jun 30, 2023 going ex on Jun 08, 2023
Jun 09, 2023
Jun 30, 2023
Jun 08, 2023
Jan 24, 2023
BDX.NB Interim Cash Dividend of gross USD 0.91 paid on Mar 31, 2023 going ex on Mar 09, 2023
Mar 10, 2023
Mar 31, 2023
Mar 09, 2023
Nov 10, 2022
BDX.NB Final Cash Dividend of gross USD 0.91 paid on Dec 30, 2022 going ex on Dec 08, 2022
Dec 09, 2022
Dec 30, 2022
Dec 08, 2022
Mehr Anzeigen
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Becton Dickinson and Co?
Die fünf größten Anteilseigner von Becton Dickinson and Co sind:
The Vanguard Group, Inc. hält 32.17M Aktien, was 11.22% der Gesamtaktien entspricht.
T. Rowe Price Investment Management, Inc. hält 16.18M Aktien, was 5.64% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 15.15M Aktien, was 5.29% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 13.41M Aktien, was 4.68% der Gesamtaktien entspricht.
First Eagle Investment Management, L.L.C. hält 8.79M Aktien, was 3.07% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 32.17M Aktien, was 11.22% der Gesamtaktien entspricht.
T. Rowe Price Investment Management, Inc. hält 16.18M Aktien, was 5.64% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 15.15M Aktien, was 5.29% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 13.41M Aktien, was 4.68% der Gesamtaktien entspricht.
First Eagle Investment Management, L.L.C. hält 8.79M Aktien, was 3.07% der Gesamtaktien entspricht.
Was sind die drei wichtigsten Anteilseigner-Typen von Becton Dickinson and Co?
Die drei wichtigsten Anteilseigner-Typen von Becton Dickinson and Co sind:
The Vanguard Group, Inc.
T. Rowe Price Investment Management, Inc.
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
T. Rowe Price Investment Management, Inc.
BlackRock Institutional Trust Company, N.A.
Wie viele Institutionen halten Anteile an Becton Dickinson and Co (BDX)?
Mit Stand vom 2025Q3 halten 2848 Institutionen Anteile an Becton Dickinson and Co, mit einem Gesamtmarktwert von etwa 265.27M, was 92.55% der Gesamtanteile entspricht. Im Vergleich zum 2025Q2 ist der institutionelle Aktienbesitz um 0.19% gestiegen.
Was ist die größte Einnahmequelle von Becton Dickinson and Co?
Am FY2025Q3 erzielte das Geschäft mit Medication Delivery Solutions für Becton Dickinson and Co den höchsten Umsatz in Höhe von 1.13B, was 20.55% des Gesamtumsatzes entspricht.
